|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-7-8
|
|
pubmed:abstractText |
Topical corticosteroids are the primary treatment for mild to moderate psoriasis. Foam preparations of corticosteroids offer potential cosmetic and pharmacodynamic advantages over cream and ointment vehicles. A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0011-9059
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
269-74
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12100701-Administration, Topical,
pubmed-meshheading:12100701-Adolescent,
pubmed-meshheading:12100701-Adult,
pubmed-meshheading:12100701-Anti-Inflammatory Agents,
pubmed-meshheading:12100701-Clobetasol,
pubmed-meshheading:12100701-Double-Blind Method,
pubmed-meshheading:12100701-Drug Compounding,
pubmed-meshheading:12100701-Female,
pubmed-meshheading:12100701-Follow-Up Studies,
pubmed-meshheading:12100701-Glucocorticoids,
pubmed-meshheading:12100701-Humans,
pubmed-meshheading:12100701-Male,
pubmed-meshheading:12100701-Middle Aged,
pubmed-meshheading:12100701-Outcome Assessment (Health Care),
pubmed-meshheading:12100701-Psoriasis,
pubmed-meshheading:12100701-Severity of Illness Index,
pubmed-meshheading:12100701-Time Factors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
|
|
pubmed:affiliation |
Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029-6574, USA. sinaiderom@aol.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
